Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer
暂无分享,去创建一个
N. Agarwal | O. Smaletz | E. Antonarakis | C. Sternberg | A. Bryce | A. Alva | P. Barata | C. Albany | Heather H. Cheng | P. Vlachostergios | M. Taplin | R. Aggarwal | Hao Wang | W. Fu | A. Sartor | F. Taza | C. H. Marshall | Alexandra O. Sokolova | D. Bastos | Jacob E. Berchuck | Ryan Ashkar | N. Adra | C. Su | Albert E. Holler | Adam Kessel | N. Nafissi | J. Berchuck | Heather H. Cheng
[1] F. Saad,et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[2] E. Antonarakis,et al. BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike? , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Antonarakis,et al. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. , 2020, European urology oncology.
[4] C. Higano,et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Tutt,et al. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. , 2020, Cancer discovery.
[6] W. Foulkes,et al. Etiologic Index - A Case-Only Measure of BRCA1/2-Associated Cancer Risk. , 2020, The New England journal of medicine.
[7] N. Agarwal,et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. , 2020, European urology.
[8] E. Antonarakis. Olaparib for DNA repair-deficient prostate cancer — one for all, or all for one? , 2020, Nature Reviews Clinical Oncology.
[9] J. Gregg,et al. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity , 2020, JCO precision oncology.
[10] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[11] F. Feng,et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.
[12] P. Kantoff,et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. , 2020, European urology.
[13] N. Tunariu,et al. Genomics of lethal prostate cancer at diagnosis and castration resistance , 2019, The Journal of clinical investigation.
[14] E. Antonarakis,et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.
[15] N. Socci,et al. Tumour lineage shapes BRCA-mediated phenotypes , 2019, Nature.
[16] J. Gregg,et al. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors , 2019, JCO precision oncology.
[17] Yi Mi Wu,et al. Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.
[18] E. Gallardo,et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Jun Luo,et al. PARP inhibition — not all gene mutations are created equal , 2018, Nature Reviews Urology.
[20] M. Rubin,et al. SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity , 2018, Clinical Cancer Research.
[21] Yi Mi Wu,et al. The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.
[22] M. Nykter,et al. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. , 2018, Cancer discovery.
[23] H. Wu,et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Zachary J. Heins,et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. , 2017, JCO precision oncology.
[25] Oliver Sartor,et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Ashworth,et al. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. , 2016, The oncologist.
[27] Ahmet Zehir,et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.
[28] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.